{"id":2612,"date":"2016-07-12T18:11:00","date_gmt":"2016-07-12T18:11:00","guid":{"rendered":"https:\/\/cdafound.org\/?p=2612"},"modified":"2025-01-15T20:26:18","modified_gmt":"2025-01-15T20:26:18","slug":"is-elimination-of-hcv-possible-in-a-country-with-low-diagnostic-rate-and-moderate-hcv-prevalence-the-case-of-greece","status":"publish","type":"post","link":"https:\/\/cdafound.org\/fr\/is-elimination-of-hcv-possible-in-a-country-with-low-diagnostic-rate-and-moderate-hcv-prevalence-the-case-of-greece\/","title":{"rendered":"L'\u00e9limination du VHC est-elle possible dans un pays \u00e0 faible taux de diagnostic et \u00e0 pr\u00e9valence mod\u00e9r\u00e9e du VHC?: Le cas de la Gr\u00e8ce"},"content":{"rendered":"

R\u00e9sum\u00e9<\/h2>\n\n\n\n

Contexte et objectif<\/h3>\n\n\n\n

Le traitement de l'h\u00e9patite C (VHC) avec des antiviraux \u00e0 action directe (AAD) sans interf\u00e9ron (IFN) devrait modifier la charge de morbidit\u00e9 future. L'objectif de cette \u00e9tude est de quantifier l'impact des AAD sans IFN sur la morbidit\u00e9 et la mortalit\u00e9 li\u00e9es au VHC en Gr\u00e8ce selon diff\u00e9rents sc\u00e9narios concernant la couverture du traitement et la pr\u00e9vention primaire, y compris la strat\u00e9gie mondiale de lutte contre l'h\u00e9patite propos\u00e9e par l'Organisation mondiale de la sant\u00e9. <\/p>\n\n\n\n

M\u00e9thodes<\/h3>\n\n\n\n

Un mod\u00e8le d\u00e9crit pr\u00e9c\u00e9demment a \u00e9t\u00e9 utilis\u00e9 pour projeter la charge de morbidit\u00e9 future jusqu'en 2030 selon des sc\u00e9narios qui incluent un traitement bas\u00e9 sur la combinaison d'IFN p\u00e9gyl\u00e9 avec de la ribavirine (cas de base) et des sc\u00e9narios utilisant des th\u00e9rapies AAD. <\/p>\n\n\n\n

R\u00e9sultats<\/h3>\n\n\n\n

Dans le sc\u00e9nario de base, une augmentation de la morbidit\u00e9 et de la mortalit\u00e9 li\u00e9es au VHC est pr\u00e9vue en Gr\u00e8ce (mortalit\u00e9 en 2030: + 23,61 TP1T par rapport \u00e0 2015). Si les AAD sont utilis\u00e9s avec la m\u00eame couverture de traitement, le nombre de cas de carcinome h\u00e9patocellulaire et de d\u00e9c\u00e8s li\u00e9s au foie devrait \u00eatre inf\u00e9rieur de 4%-7% par rapport \u00e0 2015. Avec une couverture de traitement accrue (de 2000 trait\u00e9s \/ an \u00e0 environ 5000 \/ an en 2015-2020 et 2500 \/ an par la suite), la morbidit\u00e9 et la mortalit\u00e9 diminueront de 43%-53% en 2030 par rapport \u00e0 2015. Pour atteindre les objectifs de la strat\u00e9gie mondiale de l'OMS contre l'h\u00e9patite, un nombre total de 86 500 patients atteints d'h\u00e9patite C chronique devront \u00eatre trait\u00e9s en 2016. -2030. <\/p>\n\n\n\n

Conclusions<\/h3>\n\n\n\n

L'\u00e9limination du VHC en Gr\u00e8ce d'ici 2030 n\u00e9cessite de grandes am\u00e9liorations dans la pr\u00e9vention primaire, la mise en \u0153uvre de programmes de d\u00e9pistage de grande envergure et une couverture de traitement \u00e9lev\u00e9e.<\/p>\n\n\n\n

Des pays:<\/strong> Gr\u00e8ce<\/p>\n\n

\n
Lire le rapport complet<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

Summary Background & Aim The treatment of hepatitis C (HCV) with interferon (IFN)-free Direct-Acting Antivirals (DAAs) is anticipated to change the future burden of disease. Aim of this study is to quantify the impact of IFN-free DAAs on HCV-related morbidity and mortality in Greece under different scenarios concerning treatment coverage and primary prevention, including the […]<\/p>\n","protected":false},"author":24,"featured_media":3322,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[31,10],"publication-author":[797,798,1108,494,1107,796],"class_list":["post-2612","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication","tag-elimination","tag-hcv","publication-author-gountas-i","publication-author-hatzakis-a","publication-author-papatheodoridis-g","publication-author-razavi-h","publication-author-souliotis-g","publication-author-sypsa-v"],"acf":[],"_links":{"self":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2612","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/comments?post=2612"}],"version-history":[{"count":5,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2612\/revisions"}],"predecessor-version":[{"id":7575,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2612\/revisions\/7575"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media\/3322"}],"wp:attachment":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media?parent=2612"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/categories?post=2612"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/tags?post=2612"},{"taxonomy":"publication-author","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/publication-author?post=2612"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}